{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:17:55Z","timestamp":1792588675958,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Adiponectin, a hormone secreted by adipocytes, plays a crucial role in maintaining metabolic balance and supporting cardiovascular health. Although it is known for its protective effects, such as improving insulin sensitivity, reducing inflammation, and maintaining endothelial function, there are paradoxical associations between high adiponectin levels and increased cardiovascular mortality\u2014referred to as the \u201cadiponectin paradox\u201d\u2014which complicates its clinical interpretation. This review explores the cardioprotective effects of adiponectin in both type 1 and type 2 diabetes, focusing on its potential to regulate glucose metabolism and prevent cardiovascular complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>By reviewing key studies, the article evaluates adiponectin\u2019s diverse roles and compares its effects on cardiovascular outcomes across diabetes subtypes, especially in diabetic cardiomyopathy, with an emphasis on congestive heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The findings underscore the importance of further research into therapeutic strategies aimed at modulating adiponectin levels, particularly for individuals with diabetes and congestive heart failure. Understanding the dual nature of adiponectin\u2019s effects is critical for developing target interventions to improve cardiovascular outcomes in diabetic populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-025-01610-5","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:39:41Z","timestamp":1760337581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Cardioprotective Effects of Adiponectin in Diabetes"],"prefix":"10.1007","volume":"25","author":[{"given":"Tara","family":"Kazemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1610_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041180","volume-title":"Nutrients (Vol. 13, Issue 4)","author":"K Khoramipour","year":"2021","unstructured":"Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, Bragazzi NL. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. In: Nutrients (Vol. 13, Issue 4). MDPI AG; 2021. https:\/\/doi.org\/10.3390\/nu13041180."},{"key":"1610_CR2","doi-asserted-by":"publisher","unstructured":"Mao Y, Zhong W. Serum adiponectin concentrations as a risk factor for cardiovascular complications in type 1 diabetes. Diabetes Res Clin Pract. 2023;200 https:\/\/doi.org\/10.1016\/j.diabres.2023.110700.","DOI":"10.1016\/j.diabres.2023.110700"},{"key":"1610_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2017.03.004","volume-title":"Trends in endocrinology and metabolism (Vol. 28, Issue 7, pp. 519\u2013530)","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ma XL, Lau WB. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. In: Trends in endocrinology and metabolism (Vol. 28, Issue 7, pp. 519\u2013530). Elsevier Inc.; 2017. https:\/\/doi.org\/10.1016\/j.tem.2017.03.004."},{"issue":"1","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/BBRC.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an Adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun. 1999;257(1):79\u201383. https:\/\/doi.org\/10.1006\/BBRC.1999.0255.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1610_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2796.2011.02406.x","volume":"270","author":"C Forsblom","year":"2011","unstructured":"Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Wad\u00e9n J, Gordin D, Frystyk J, Flyvbjerg A, Groop PH. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular adip in type 1 diabetes. J Intern Med. 2011;270(4):346\u201355. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02406.x.","journal-title":"J Intern Med"},{"key":"1610_CR6","doi-asserted-by":"publisher","unstructured":"Han Y, Sun Q, Chen W, Gao Y, Ye J, Chen Y, Wang T, Gao L, Liu Y, Yang Y. New advances of adiponectin in regulating obesity and related metabolic syndromes. Journal of Pharmaceutical Analysis. 2024;14(5) https:\/\/doi.org\/10.1016\/j.jpha.2023.12.003.","DOI":"10.1016\/j.jpha.2023.12.003"},{"issue":"7","key":"1610_CR7","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784\u201392. https:\/\/doi.org\/10.1172\/JCI29126.","journal-title":"J Clin Invest"},{"issue":"11","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/nm788","volume":"8","author":"T Yamauchi","year":"2002","unstructured":"Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288\u201395. https:\/\/doi.org\/10.1038\/nm788.","journal-title":"Nat Med"},{"key":"1610_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108008","volume-title":"Pharmacology and therapeutics","author":"A Sharma","year":"2022","unstructured":"Sharma A, Mah M, Ritchie RH, de Blasio MJ. The adiponectin signaling pathway - A therapeutic target for the cardiac complications of type 2 diabetes? In: Pharmacology and therapeutics, vol. 232. Elsevier Inc; 2022. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108008."},{"key":"1610_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121266","volume-title":"Pharmaceuticals (Vol. 14, issue 12)","author":"HO Kalkman","year":"2021","unstructured":"Kalkman HO. An explanation for the adiponectin paradox. In: Pharmaceuticals (Vol. 14, issue 12). MDPI; 2021. https:\/\/doi.org\/10.3390\/ph14121266."},{"issue":"3","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/en.2014-1618","volume":"156","author":"K Matsuda","year":"2015","unstructured":"Matsuda K, Fujishima Y, Maeda N, Mori T, Hirata A, Sekimoto R, Tsushima Y, Masuda S, Yamaoka M, Inoue K, Nishizawa H, Kita S, Ranscht B, Funahashi T, Shimomura I. Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice. Endocrinology (United States). 2015;156(3):934\u201346. https:\/\/doi.org\/10.1210\/en.2014-1618.","journal-title":"Endocrinology (United States)"},{"issue":"10","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/J.BIOCHI.2012.01.017","volume":"94","author":"JM Tishinsky","year":"2012","unstructured":"Tishinsky JM, Robinson LE, Dyck DJ. Insulin-sensitizing properties of adiponectin. Biochimie. 2012;94(10):2131\u20136. https:\/\/doi.org\/10.1016\/J.BIOCHI.2012.01.017.","journal-title":"Biochimie"},{"key":"1610_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.314458","volume-title":"Circulation research (Vol. 128, issue 1, pp. 136\u2013149)","author":"S Zhao","year":"2021","unstructured":"Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. In: Circulation research (Vol. 128, issue 1, pp. 136\u2013149). Lippincott Williams and Wilkins; 2021. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.314458."},{"issue":"4","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"E271","DOI":"10.25011\/cim.v32i4.6618","volume":"32","author":"S Ljubic","year":"2009","unstructured":"Ljubic S, Boras J, Jazbec A, Phd B, Lovrencic MV, Vidjak V, Jurisic Erzen D, Mileta D. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clinical and Investigative Medicine. 2009;32(4):E271\u20139.","journal-title":"Clinical and Investigative Medicine"},{"key":"1610_CR15","doi-asserted-by":"crossref","unstructured":"Kern PA, Ranganathan S, Wood L, Ranganathan G, Li C, Ranganathan Adipose G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745\u201351. http:\/\/www.ajpendo.orgE745","DOI":"10.1152\/ajpendo.2001.280.5.E745"},{"issue":"3","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.diabres.2005.10.026","volume":"72","author":"M Furuta","year":"2006","unstructured":"Furuta M, Tamai M, Hanabusa T, Yamamoto Y, Nanjo K, Sanke T. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diabetes Res Clin Pract. 2006;72(3):302\u20137. https:\/\/doi.org\/10.1016\/j.diabres.2005.10.026.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00125-003-1074-z","volume":"46","author":"M Cnop","year":"2003","unstructured":"Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459\u201369. https:\/\/doi.org\/10.1007\/s00125-003-1074-z.","journal-title":"Diabetologia"},{"issue":"2","key":"1610_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.amjcard.2013.09.027","volume":"113","author":"MG Karas","year":"2014","unstructured":"Karas MG, Benkeser D, Arnold AM, Bartz TM, Djousse L, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, Gottdiener JS, Defilippi CR, Kizer JR. Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults \u226565 years of age (from the cardiovascular health study). Am J Cardiol. 2014;113(2):328\u201334. https:\/\/doi.org\/10.1016\/j.amjcard.2013.09.027.","journal-title":"Am J Cardiol"},{"key":"1610_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/jhh.2008.75","volume":"22","author":"E Teijeira-Fernandez","year":"2008","unstructured":"Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B, Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens. 2008;22:856\u201363.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2337\/dbi17-0016","volume":"67","author":"C Menzaghi","year":"2018","unstructured":"Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. 2018;67(1):12\u201322. https:\/\/doi.org\/10.2337\/dbi17-0016.","journal-title":"Diabetes"},{"issue":"9","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.2337\/diabetes.51.9.2734","volume":"51","author":"H Nishizawa","year":"2002","unstructured":"Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens Decrease Plasma Adiponectin, an Insulin-Sensitizing Adipocyte-Derived Protein. Diabetes. 2002;51(9):2734\u201341. https:\/\/doi.org\/10.2337\/diabetes.51.9.2734.","journal-title":"Diabetes"},{"issue":"2","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/09513590400020989","volume":"20","author":"A Milewicz","year":"2005","unstructured":"Milewicz A, Zatonska K, Demissie M, J\u00eadrzejuk D, Dunajska K, Ilow R, Lwow F. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol. 2005;20(2):68\u201373. https:\/\/doi.org\/10.1080\/09513590400020989.","journal-title":"Gynecol Endocrinol"},{"issue":"11","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3275\/9001","volume":"36","author":"S Matsui","year":"2013","unstructured":"Matsui S, Yasui T, Tani A, Kato T, Kunimi K, Uemura H, Kuwahara A, Matsuzaki T, Irahara M. Difference in the ratio of high-molecular weight (HMW) to total adiponectin and HMW adiponectin in late post-menopausal women. J Endocrinol Investig. 2013;36(11):982\u20135. https:\/\/doi.org\/10.3275\/9001. Epub 2013 Jun 10","journal-title":"J Endocrinol Investig"},{"issue":"7","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"e019173","DOI":"10.1161\/JAHA.120.019173","volume":"10","author":"SA Everson-Rose","year":"2021","unstructured":"Everson-Rose SA, Barinas-Mitchell EJM, el Khoudary SR, Huang HH, Wang Q, Janssen I, Thurston RC, Jackson EA, Lewis ME, Karvonen-Gutierrez C, Mancuso P, Derby CA. Adipokines and subclinical cardiovascular disease in post-menopausal women: study of women\u2019s health across the nation. J Am Heart Assoc. 2021;10(7):e019173. https:\/\/doi.org\/10.1161\/JAHA.120.019173.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/aje\/kwm125","volume":"166","author":"DM Maahs","year":"2007","unstructured":"Maahs DM, Ogden LG, Snell-Bergeon JK, Kinney GL, Wadwa RP, Hokanson JE, Dabelea D, Kretowski A, Eckel RH, Rewers M. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol. 2007;166(6):731\u201340. https:\/\/doi.org\/10.1093\/aje\/kwm125.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00125-005-1850-z","volume":"48","author":"J Frystyk","year":"2005","unstructured":"Frystyk J, Tarnow L, Krarup Hansen T, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005;48(9):1911\u20138. https:\/\/doi.org\/10.1007\/s00125-005-1850-z.","journal-title":"Diabetologia"},{"issue":"2","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/dmrr.2378","volume":"29","author":"MN Pham","year":"2013","unstructured":"Pham MN, Kolb H, Mandrup-Poulsen T, Battelino T, Ludvigsson J, Pozzilli P, Roden M, Schloot NC. Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes Metab Res Rev. 2013;29(2):166\u201370. https:\/\/doi.org\/10.1002\/dmrr.2378.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1210\/me.2005-0390","volume":"20","author":"AA Richards","year":"2006","unstructured":"Richards AA, Stephens T, Charlton HK, Jones A, Macdonald GA, Prins JB, Whitehead JP. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol. 2006;20(7):1673\u201387. https:\/\/doi.org\/10.1210\/me.2005-0390.","journal-title":"Mol Endocrinol"},{"issue":"8","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"E1065","DOI":"10.1210\/jc.2015-1275","volume":"100","author":"TP Combs","year":"2015","unstructured":"Combs TP, Snell-Bergeon JK, Maahs DM, Bergman BC, Lamarche M, Iberkleid L, AbdelBaky O, Tisch R, Scherer PE, Marliss EB. Adiponectin-SOGA dissociation in type 1 diabetes. J Clin Endocrinol Metab. 2015;100(8):E1065\u201373. https:\/\/doi.org\/10.1210\/jc.2015-1275.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1016\/j.febslet.2007.06.031","volume":"581","author":"JEP Brown","year":"2007","unstructured":"Brown JEP, Onyango DJ, Dunmore SJ. Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett. 2007;581(17):3273\u20136. https:\/\/doi.org\/10.1016\/j.febslet.2007.06.031.","journal-title":"FEBS Lett"},{"issue":"7121","key":"1610_CR31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nature05483","volume":"444","author":"ED Rosen","year":"2006","unstructured":"Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444(7121):847\u201353. https:\/\/doi.org\/10.1038\/nature05483.","journal-title":"Nature"},{"key":"1610_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092022","volume-title":"Nutrients (Vol. 11, issue 9)","author":"AIS Sobczak","year":"2019","unstructured":"Sobczak AIS, Blindauer CA, Stewart AJ. Changes in plasma free fatty acids associated with type-2 diabetes. In: Nutrients (Vol. 11, issue 9). MDPI AG; 2019. https:\/\/doi.org\/10.3390\/nu11092022."},{"key":"1610_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071430","volume-title":"Pharmaceutics (Vol. 14, issue 7)","author":"MA Aljafary","year":"2022","unstructured":"Aljafary MA, Al-Suhaimi EA. Adiponectin system (rescue hormone): the missing link between metabolic and cardiovascular diseases. In: Pharmaceutics (Vol. 14, issue 7). MDPI; 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14071430."},{"key":"1610_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2017.224R","volume":"15","author":"C Farah","year":"2018","unstructured":"Farah C, Michel L, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15:292\u2013316. https:\/\/doi.org\/10.1038\/nrcardio.2017.224R.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.3892\/mmr.2015.3899","volume":"12","author":"W Zhang","year":"2015","unstructured":"Zhang W, Shu C, Li Q, Li M, Li X. Adiponectin affects vascular smooth muscle cell proliferation and apoptosis through modulation of the mitofusin-2-mediated Ras-Raf-Erk1\/2 signaling pathway. Mol Med Rep. 2015;12(3):4703\u20137. https:\/\/doi.org\/10.3892\/mmr.2015.3899.","journal-title":"Mol Med Rep"},{"key":"1610_CR36","volume-title":"Adipocyte-derived plasma protein, adiponectin","author":"N Ouchi","year":"2001","unstructured":"Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin. Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages; 2001. http:\/\/www.circulationaha.org"},{"issue":"1","key":"1610_CR37","first-page":"450","volume":"8","author":"B Liang","year":"2015","unstructured":"Liang B, Wang X, Guo X, Yang Z, Bai R, Liu M, Xiao C, Bian Y. Adiponectin upregulates ABCA1 expression through liver X receptor alpha signaling pathway in RAW 264.7 macrophages. Int J Clin Exp Pathol. 2015;8(1):450\u20137. PMID: 25755733; PMCID: PMC4348878","journal-title":"Int J Clin Exp Pathol"},{"key":"1610_CR38","doi-asserted-by":"crossref","unstructured":"Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care. 2004;27(7):1680\u20137. http:\/\/diabetesjournals.org\/care\/article-pdf\/27\/7\/1680\/665048\/zdc00704001680.pdf","DOI":"10.2337\/diacare.27.7.1680"},{"issue":"7","key":"1610_CR39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.febslet.2008.03.002","volume":"582","author":"Y Ikeda","year":"2008","unstructured":"Ikeda Y, Ohashi K, Shibata R, Pimentel DR, Kihara S, Ouchi N, Walsh K. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett. 2008;582(7):1147\u201350. https:\/\/doi.org\/10.1016\/j.febslet.2008.03.002.","journal-title":"FEBS Lett"},{"issue":"1","key":"1610_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00395-022-00939-2","volume":"117","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Liu C, Xu S, Wang J, Guo F, Duan S, Deng Q, Sun J, Yu F, Zhou Y, Wang M, Wang Y, Zhou L, Jiang H, Yu L. Metabolism regulator adiponectin prevents cardiac remodeling and ventricular arrhythmias via sympathetic modulation in a myocardial infarction model. Basic Res Cardiol. 2022;117(1):34. https:\/\/doi.org\/10.1007\/s00395-022-00939-2.","journal-title":"Basic Res Cardiol."},{"issue":"10","key":"1610_CR41","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1295","volume":"11","author":"R Shibata","year":"2005","unstructured":"Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11(10):1096\u2013103. https:\/\/doi.org\/10.1038\/nm1295.","journal-title":"Nat Med"},{"issue":"7","key":"1610_CR42","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/ATVBAHA.108.16330362","volume":"28","author":"S Devaraj","year":"2008","unstructured":"Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol. 2008;28(7):1368\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.108.16330362.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1610_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.metabol.2003.12.008","volume":"53","author":"T Kazumi","year":"2004","unstructured":"Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metab Clin Exp. 2004;53(5):589\u201393. https:\/\/doi.org\/10.1016\/j.metabol.2003.12.008.","journal-title":"Metab Clin Exp"},{"issue":"3","key":"1610_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/2047487313514894","volume":"22","author":"S Lindberg","year":"2015","unstructured":"Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol. 2015;22(3):276\u201383. https:\/\/doi.org\/10.1177\/2047487313514894.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1610_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00125-004-1597-y","volume":"48","author":"T Costacou","year":"2005","unstructured":"Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study. Diabetologia. 2005;48(1):41\u20138. https:\/\/doi.org\/10.1007\/s00125-004-1597-y.","journal-title":"Diabetologia"},{"key":"1610_CR46","doi-asserted-by":"publisher","unstructured":"Tu WJ, Qiu HC, Liu YK, Liu Q, Zeng X, Zhao J. Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke. Cardiovasc Diabetol. 2020;19(1) https:\/\/doi.org\/10.1186\/s12933-020-01096-3.","DOI":"10.1186\/s12933-020-01096-3"},{"issue":"10","key":"1610_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/a-1239-4349","volume":"52","author":"EA Francischetti","year":"2020","unstructured":"Francischetti EA, Dezonne RS, Pereira CM, de Moraes Martins CJ, Celoria BMJ, de Oliveira PAC, de Abreu VG. Insights into the controversial aspects of adiponectin in Cardiometabolic disorders. Horm Metab Res. 2020;52(10):695\u2013707. https:\/\/doi.org\/10.1055\/a-1239-4349.","journal-title":"Horm Metab Res"},{"issue":"9","key":"1610_CR48","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.2337\/dc11-2215","volume":"35","author":"JR Singer","year":"2012","unstructured":"Singer JR, Weinstock R, Palmas W, Shea S, Teresi J, Luchsinger JA. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care. 2012;35(9):1858\u201363. https:\/\/doi.org\/10.2337\/dc11-2215.","journal-title":"Diabetes Care"},{"issue":"2","key":"1610_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.atherosclerosis.2011.11.038","volume":"220","author":"AL Beatty","year":"2012","unstructured":"Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: Data from the heart and soul study. Atherosclerosis. 2012;220(2):587\u201392.","journal-title":"Atherosclerosis"},{"key":"1610_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab199","volume-title":"Cardiovascular research (Vol. 118, Issue 9, pp. 2074\u20132084)","author":"AY Jang","year":"2022","unstructured":"Jang AY, Scherer PE, Kim JY, Lim S, Koh KK. Adiponectin and cardiometabolic trait and mortality: where do we go? In: Cardiovascular research (Vol. 118, Issue 9, pp. 2074\u20132084). Oxford University Press; 2022. https:\/\/doi.org\/10.1093\/cvr\/cvab199."},{"issue":"6","key":"1610_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ejhf.82","volume":"16","author":"S Lindberg","year":"2014","unstructured":"Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Mogelvang R. Cardio-adipose tissue cross-talk: relationship between adiponectin, plasma pro brain natriuretic peptide and incident heart failure. Eur J Heart Fail. 2014;16(6):633\u20138. https:\/\/doi.org\/10.1002\/ejhf.82.","journal-title":"Eur J Heart Fail"},{"key":"1610_CR52","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2020-0095","volume-title":"Future Cardiology (Vol. 17, issue 4, pp. 755\u2013762)","author":"H Mado","year":"2021","unstructured":"Mado H, Szczurek W, G\u0105sior M, Szygu\u0142a-Jurkiewicz B. Adiponectin in heart failure. In: Future Cardiology (Vol. 17, issue 4, pp. 755\u2013762). Future Medicine Ltd; 2021. https:\/\/doi.org\/10.2217\/fca-2020-0095."},{"issue":"4","key":"1610_CR53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/oby.20260","volume":"21","author":"L Djouss\u00e9","year":"2013","unstructured":"Djouss\u00e9 L, Wilk JB, Hanson NQ, Glynn RJ, Tsai MY, Gaziano JM. Association between adiponectin and heart failure risk in the physicians\u2019 health study. Obesity. 2013;21(4):831\u20134. https:\/\/doi.org\/10.1002\/oby.20260.","journal-title":"Obesity"},{"issue":"3","key":"1610_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/CIRCHEARTFAILURE.111.964031","volume":"5","author":"RS Khan","year":"2012","unstructured":"Khan RS, Kato TS, Choksh A, Chew M, Yu S, Wu C, Singh P, Cheema FH, Takayama H, Harris C, Reyes-Soffer G, Kn\u00f6ll R, Milting H, Naka Y, Mancini D, Schulze PC. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure correction after ventricular assist device implantation. Circ Heart Fail. 2012;5(3):340\u20138. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.964031.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1610_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3349\/ymj.2012.53.1.91","volume":"53","author":"H Won","year":"2012","unstructured":"Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, Lee SH, Jang Y, Chung N. Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J. 2012;53(1):91\u20138. https:\/\/doi.org\/10.3349\/ymj.2012.53.1.91.","journal-title":"Yonsei Med J"},{"issue":"2","key":"1610_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2007.11.040","volume":"132","author":"H Takano","year":"2009","unstructured":"Takano H, Obata J, Kodama Y, Kitta Y, Nakamura T, Mende A, Kawabata KI, Saito Y, Fujioka D, Kobayashi T, Yano T, Sano K, Kugiyama K. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol. 2009;132(2):221\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2007.11.040.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1610_CR57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1253\/circj.71.623","volume":"71","author":"T Tamura","year":"2007","unstructured":"Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, Horiuchi H, Nakagawa Y, Kita T, Kimura T. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J. 2007;71(5):623\u201330. https:\/\/doi.org\/10.1253\/circj.71.623.","journal-title":"Circ J"},{"issue":"22","key":"1610_CR58","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.jacc.2009.02.038","volume":"53","author":"O Tsukamoto","year":"2009","unstructured":"Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53(22):2070\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.038.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1610_CR59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1475-2840-11-151","volume":"18","author":"S Baldasseroni","year":"2012","unstructured":"Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, Foschini A, Marella A, Pratesi A, Scarantino S, Fumagalli S, Monami M, Mannucci E, Marchionni N, Tarantini F. Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetol. 2012;18(11):151. https:\/\/doi.org\/10.1186\/1475-2840-11-151. PMID: 23249664; PMCID: PMC3558365","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"1610_CR60","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.104.530972","volume":"112","author":"C Kistorp","year":"2005","unstructured":"Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112(12):1756\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.530972.","journal-title":"Circulation"},{"issue":"8","key":"1610_CR61","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.numecd.2015.04.005","volume":"25","author":"MA Allison","year":"2015","unstructured":"Allison MA, Criqui MH, Maisel AS, Daniels LB, Roberts CK, Polak JF, Cushman M. Adiponectin is independently associated with NT-proBNP: The multi-ethnic study of atherosclerosis. Nutr Metab Cardiovasc Dis. 2015;25(8):780\u20136. https:\/\/doi.org\/10.1016\/j.numecd.2015.04.005.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7477","key":"1610_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature12656","volume":"503","author":"M Okada-Iwabu","year":"2013","unstructured":"Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami KI, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493\u20139. https:\/\/doi.org\/10.1038\/nature12656.","journal-title":"Nature"},{"issue":"4","key":"1610_CR63","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/J.CARDIORES.2005.04.018","volume":"67","author":"Y Liao","year":"2005","unstructured":"Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67(4):705\u201313. https:\/\/doi.org\/10.1016\/J.CARDIORES.2005.04.018.","journal-title":"Cardiovasc Res"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-025-01610-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:58:52Z","timestamp":1770292732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-025-01610-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s11892-025-01610-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"8 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"53"}}